δ Sarcoglycan Antibody

About the Target

35DAG is a target of interest in many antibody-based workflows. δ-Sarcoglycan is a type II transmembrane glycoprotein and a core component of the sarcoglycan complex within the dystrophin-glycoprotein complex (DGC), which stabilizes the plasma membrane in muscle cells. Structurally, it contains a short cytoplasmic N-terminus, a single transmembrane domain, an extracellular region with one N-linked glycosylation site, and a conserved cysteine-rich cluster at the C-terminus resembling epidermal growth factor-like motifs, although an alternatively spliced form lacking this region is also expressed. Depending on the literature source, 35DAG may also be discussed as delta Sarcoglycan and Delta-sarcoglycan.

Reported cellular context includes cell membrane, cytoplasm, cytoskeleton, and membrane, which can matter when signal is compared across treatments or changing cell states. Following 35DAG across matched perturbations can help separate abundance effects from shifts in localization, complex assembly, or pathway state.

Research Context

35DAG is commonly interpreted in the context of cardiovascular research, and readouts are often stronger when a study separates expression changes from compartment-level redistribution. When reported signal spans cell membrane, cytoplasm, and cytoskeleton, a defined reference condition can make comparisons more interpretable across perturbations, passages, or replicate sets.

Consider these angles when interpreting target-level changes:

• apparent redistribution between cell membrane, cytoplasm, and cytoskeleton across matched conditions
• changes linked to vascular, contractile, or hemodynamic cell-state cues
• co-patterning with orthogonal markers and control conditions that clarify pathway state
• time-matched comparisons so changes reflect biology rather than handling or sampling drift

Variant Considerations

If your project spans exploratory questions, the regular version offers a balanced option for establishing baseline signal behavior for 35DAG. This can help when protocols evolve over time and the goal is to compare experiments using a stable reference workflow.

Standardize sampling time, control choice, and downstream analysis thresholds so apparent differences in 35DAG reflect biology rather than handling. When interpreting 35DAG, it is often useful to decide early whether the main question is overall abundance, compartmental enrichment, or context-dependent redistribution.

For multi-run studies, a shared reference condition can keep 35DAG trends easier to compare across datasets. That kind of consistency is especially helpful when follow-up work expands to new perturbations, model systems, or longitudinal collections.